Price T Rowe Associates Inc. MD Cuts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT)

Price T Rowe Associates Inc. MD trimmed its holdings in shares of Applied Therapeutics, Inc. (NASDAQ:APLT) by 96.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 34,763 shares of the company’s stock after selling 986,108 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Applied Therapeutics were worth $30,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of APLT. Private Advisor Group LLC purchased a new position in Applied Therapeutics during the fourth quarter valued at approximately $35,000. SG Americas Securities LLC increased its holdings in Applied Therapeutics by 169.0% during the fourth quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after buying an additional 25,601 shares during the period. Intech Investment Management LLC increased its holdings in Applied Therapeutics by 176.1% during the fourth quarter. Intech Investment Management LLC now owns 52,631 shares of the company’s stock valued at $45,000 after buying an additional 33,567 shares during the period. Dark Forest Capital Management LP increased its holdings in Applied Therapeutics by 54.5% during the fourth quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company’s stock valued at $46,000 after buying an additional 18,949 shares during the period. Finally, Legal & General Group Plc increased its holdings in Applied Therapeutics by 293.9% during the fourth quarter. Legal & General Group Plc now owns 84,018 shares of the company’s stock valued at $72,000 after buying an additional 62,686 shares during the period. 98.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Royal Bank of Canada restated a “sector perform” rating and issued a $1.50 target price on shares of Applied Therapeutics in a research note on Wednesday, May 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.10.

Applied Therapeutics Stock Up 22.8%

Shares of APLT opened at $0.60 on Monday. The company has a market cap of $85.36 million, a price-to-earnings ratio of -0.37 and a beta of 2.00. Applied Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $10.62. The company has a 50 day moving average of $0.43 and a two-hundred day moving average of $1.86.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings data on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.61 million. On average, sell-side analysts expect that Applied Therapeutics, Inc. will post -0.65 EPS for the current year.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.